SEI EXCHANGE TRADED FDS SEI Enhanced Low Volatility U.S. Large Cap ETF SELV 深 滬
已收盤 11-14 16:00:00 美东时间
31.77
-0.071
-0.22%
華盛通- 最 高31.91
- 今 開31.79
- 成交量 5073股
- 最 低 31.77
- 昨 收 31.8407
- 總市值 1.63亿
- 52周最高 32.06
- 市盈率 靜 --
- 換手率 0.10%
- 52周最低 27.342
- 委 比 0.00%
- 總股本 512.43万
- 歷史最高 32.06
- 量 比 0.09
- 振 幅 0.44%
- 歷史最低 20.5739
- 每 手 1
- 風險率 0.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Trump calls for federal money to bypass ‘BIG, BAD’ health insurers
President Donald Trump called for a significant shift in how federal funds for healthcare are distributed. In a series of posts on Truth Social, Trump proposed that the “hundreds of billions of dolla...
11-09 20:48
Palvella Receives Second-Year FDA Grant to Fund Phase 3 Trial of QTORIN for Rare Skin Disease
(NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases
10-13 19:35
Palvella Therapeutics Receives U.S. Patent Covering 0.1–20% Anhydrous Compositions Of Rapamycin And Other mTOR Inhibitors
New intellectual property builds on Palvella's multi-layered exclusivity strategyPatent term expected through at least 2038- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical
06-18 19:34
Palvella Therapeutics Receives The Initial Proceeds From A Previously Announced Grant From FDA Office Of Orphan Products Development, The Grant Supports Its Ongoing Phase 3 SELVA trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations
FDA Orphan Products Grants are awarded based on rigorous scientific and technical review by rare disease and regulatory expertsUp to $2.6 million in non-dilutive funding anticipated over the grant periodTop-line data
06-09 19:36
Vicor to Present at WCX 2025 in Detroit
How to rapidly implement bi-directional 800V to 48V/12V DC-DC conversion using ...
04-01 21:10
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical com...
2024-07-24 18:30
Rule 8.1 Dealing Disclosure (Horizon Therapeutics Plc)
PDF Version DUBLIN--(BUSINESS WIRE)--Sep. 25, 2023-- IRISH TAKEOVER PANEL D...
2023-09-25 12:00
